Cargando…

Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Detalles Bibliográficos
Autores principales:	Piquet, Amanda L., Corboy, John R., Vollmer, Timothy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170321/ https://www.ncbi.nlm.nih.gov/pubmed/34104219 http://dx.doi.org/10.1177/17562864211019567

Ejemplares similares

Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Petereit, Hela-Felicitas, et al.
Publicado: (2021)

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Serious safety events in rituximab‐treated multiple sclerosis and related disorders
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies
por: Ali, Ahya, et al.
Publicado: (2021)

Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis
por: Vollmer, Brandi L., et al.
Publicado: (2022)

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
por: Dominelli, Federica, et al.
Publicado: (2022)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
por: Capuano, Rocco, et al.
Publicado: (2021)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Livedoid skin reaction and mRNA Covid-19 vaccine: correspondence
por: Mungunpuntipantip, Rujittika, et al.
Publicado: (2023)

Humoral response to COVID-19 vaccination and maintenance hemodialysis: Correspondence
por: Mungmunpuntipantip, Rujititka, et al.
Publicado: (2023)

Multiple sclerosis patients’ response to COVID-19 pandemic and vaccination: correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2023)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

Humoral response to a fourth dose of mRNA vaccine in kidney transplant recipient responders to three doses of mRNA vaccine
por: de Nattes, Tristan, et al.
Publicado: (2022)

Emerging therapies for treatment of multiple sclerosis
por: Corboy, John R, et al.
Publicado: (2010)

CMR Imaging After Myocarditis Associated with mRNA COVID-19 Vaccine: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
por: Capone, Fioravante, et al.
Publicado: (2021)

mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
por: Tütüncü, Melih, et al.
Publicado: (2023)

Author response to comment on: Alopecia in multiple sclerosis patients treated with disease modifying therapies
por: Porwal, Mokshal H., et al.
Publicado: (2022)

Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies
por: Nicolas, Philippe, et al.
Publicado: (2022)

An autopsy case report of aortic dissection after mRNA COVID-19 vaccination: correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2023)

Delayed skin reactions and mRNA vaccines against SARS-CoV-2: correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
por: Ciampi, Ethel, et al.
Publicado: (2022)

Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis
por: Breu, Markus, et al.
Publicado: (2023)

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2021)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020)

Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
por: Habek, Mario, et al.
Publicado: (2021)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
por: Achtnichts, Lutz, et al.
Publicado: (2022)

Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient
por: Jakimovski, Dejan, et al.
Publicado: (2021)

Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients
por: Telesford, Kiel M., et al.
Publicado: (2023)

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis()
por: Novak, Frederik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qnrl600112p6jj5rshnv8k7sn8